STRATA Skin Sciences (NASDAQ: SSKN) Announces Favorable Court Order Against LaserOptek and Affiliates

On November 11, 2024, STRATA Skin Sciences, Inc. filed a Form 8-K with the Securities and Exchange Commission to report a recent court order favoring the company in a legal dispute against LaserOptek America Corp. and related entities. The court order, issued by the United States District Court for the Eastern District of Pennsylvania, prohibits LaserOptek and affiliated parties from engaging in certain marketing practices related to Pallas lasers in the United States.

The litigation, which began on August 19, 2024, saw STRATA filing a Complaint and a Motion for a Preliminary Injunction against LaserOptek, Monarch Aesthetic Services, Inc. d/b/a Monarch Laser Services, and The Pinnacle Health Group. The court order, issued on November 8, 2024, bars LaserOptek and its affiliates from making any claims that imply treatments with Pallas laser systems are reimbursable using specific CPT codes. Additionally, they are restrained from making false or misleading statements about Pallas lasers or STRATA’s lasers in their marketing activities within the United States.

Dr. Dolev Rafaeli, President and CEO of STRATA Skin Sciences, expressed satisfaction with the preliminary resolution, emphasizing the importance of defending users, patients, and partner clinics against misleading claims. The company intends to pursue further legal actions to seek equitable and monetary relief from LaserOptek and their associates.

LaserOptek, a Korean company traded on the KOSDAQ exchange, is the manufacturer of the Pallas line of solid-state laser medical devices. The legal dispute primarily revolves around the marketing and reimbursement practices associated with LaserOptek’s products.

STRATA Skin Sciences, a medical technology company focused on developing innovative products for treating dermatologic conditions, is recognized for its XTRAC excimer laser, VTRAC lamp systems, and TheraClear X Acne Therapy System. Through its Partnership Program in the U.S., STRATA offers a unique fee structure, training, and support to healthcare practices utilizing its technologies.

This press release contains forward-looking statements that involve uncertainties and potential changes in circumstances. Actual results may vary from the Company’s expectations due to various factors. Interested parties are encouraged to review the Company’s SEC disclosures for more information.

Investors seeking further information can contact CORE IR at 516-222-2560 or via email at [email protected].

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read STRATA Skin Sciences’s 8K filing here.

About STRATA Skin Sciences

STRATA Skin Sciences, Inc, a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment.